MK-6837 has been discontinued, the company discloses.
ApexOnco Front Page
Recent articles
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
A phase 1 study of OKI-219 reads out imminently.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
After Genmab’s exit two more ADCs enter human trials.
A new phase 3, Manifest-3, will start in April to support US filing.
The company takes a PD-L1 x VEGF asset into phase 3.
